

Announcement

Ferring Pharmaceuticals appoints Tony Volpe as Business Unit Head, Specialty, for its Canadian operation



Tony Volpe,
Business Unit Head,
Specialty,
Ferring Pharmaceuticals
Canada



Michael Seckler, General Manager of Ferring Canada, is pleased to announce the appointment of Tony Volpe to the position of Business Unit Head, Specialty, effective February 15, 2016.

As a pharmaceuticals business leader with more than 25 years of experience, Tony comes to Ferring with demonstrated success in commercial growth, profit and loss management, portfolio and life cycle optimization, strategy development, sales execution, and building and managing high-performance teams.

Most recently, Tony held the position of Vice-President, Takeda Canada, Marketing and Sales, Specialty, where, over the last four years, he built and led the specialty business unit for gastroenterology (GI), oncology, and nephrology. His focus included the pre-launch and launch of a new nephrology agent and, more recently, the launch of an inflammatory bowel disease (IBD) biologic in Canada.

Over the years, Tony has held additional senior-level positions at a number of organizations within Canada, including Business Unit Director, Oncology, and Regional Sales Manager, Oncology, at Roche; Regional Sales Manager, IBD, Rheumatoid Arthritis, Dermatology, and GI-virology, at Schering Canada; and several senior marketing roles within oncology, HIV, vaccines, GI-virology, and prostate and bladder cancer business units at other major Canadian pharmaceutical companies.

Tony holds a bachelor of arts (honours) from York University and a master of business administration with a specialization in marketing from Dalhousie University.

“I am very pleased that Tony will join Ferring, bringing his proven track record of pharmaceutical sales and marketing leadership to Ferring. Ferring strives for the highest quality, and I sincerely believe that Tony will be a great addition to Ferring Canada,” says Mr. Seckler.

CPM

Headquartered in Switzerland, **Ferring Pharmaceuticals** is a research-driven, specialty biopharmaceutical group that is active in global markets. The company identifies, develops, and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology, and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries, employs 5,000 people throughout the world, and markets its products in 110 countries.

Ferring Canada is the Canadian subsidiary of Ferring Pharmaceuticals. Ferring Canada started its operations in 1987 with just three employees. Today, Ferring Canada employs nearly 90 employees and sees considerable growth ahead as it continues to bring valuable new products to the Canadian marketplace. Ferring Canada's therapeutic focus is on urology, gastroenterology, and reproductive health. Ferring Canada is committed to providing innovative medication that will help Canadians have an even better quality of life in the years to come.

To learn more about Ferring or its products, visit www.ferring.ca